Biomea Fusion reports Phase 1 weight-loss data for oral GLP-1 BMF-650
Biomea Fusion has published Phase 1 results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist, reporting consistent weight reduction and encouraging tolerability across five multiple ascending dose cohorts over four weeks of treatment.
In the outpatient cohorts (Cohorts 1 to 4), mean weight reduction at Day 29 ranged from 1.5% to 3.2%, against 0.1% for pooled placebo. At doses of 200 mg or higher once daily, the mean weekly loss across those cohorts averaged approximately 0.97 kg. A fifth, confined cohort testing a rapid one-step titration to 400 mg once daily recorded a mean Day 29 weight loss of 6.1%, though Biomea cautioned that the confinement setting appeared to influence eating behaviour among both active and placebo participants, and said Cohort 5 results should be read separately from the outpatient data.
Safety and dosing profile
Across all five active multiple ascending dose cohorts, encompassing 40 participants, all treatment-emergent adverse events were rated mild or moderate. There were no severe or serious events, no dose modifications linked to tolerability, and no discontinuations. In the highest-dose group, nausea and vomiting were each reported in 12.5% of participants, constipation in 25%, and diarrhoea in none. No elevations in liver enzymes ALT or AST were observed. Biomea noted the findings are preliminary, reflecting four weeks of treatment.
The company said BMF-650 was explicitly designed to separate gastrointestinal receptor agonism from the systemic exposure required for weight loss, aiming to improve tolerability relative to other oral GLP-1 agents. Thorsten Kirschberg, Executive Vice President of Research and programme lead for BMF-650, said the molecule demonstrated "good oral absorption with consistent and sustained systemic exposure" and that the data support testing a potential no-titration regimen. Many approved and late-stage oral GLP-1 candidates require titration schedules extending five months or more; the ability to reach a target dose in a single step would be a meaningful practical advantage if it holds in longer studies.
Market context and development path
The oral GLP-1 receptor agonist field has become intensely competitive since semaglutide's oral formulation demonstrated commercial viability. A number of clinical-stage and preclinical programmes from both large pharmaceutical companies and biotechs are pursuing improved tolerability, simpler dosing, and differentiated pharmacokinetics as their primary points of distinction. Biomea is positioning BMF-650 within that cohort, emphasising persistence on chronic therapy rather than headline weight-loss magnitude.
Biomea was candid that its primary development priority remains icovamenib, its menin inhibitor in Phase 2 trials for type 1 and type 2 diabetes. For BMF-650, the company said it intends to complete longer-term toxicology studies and pursue a strategic partnership, which could include a licensing arrangement covering late-stage development and commercialisation. The programme is not being advanced to Phase 2 on Biomea's own balance sheet in the near term.
Interim chief executive Mick Hitchcock said the Phase 1 results "warrant further evaluation, including through potential collaborations," framing the data package as sufficient to attract a partner rather than to justify independent advancement. Whether that framing proves persuasive will depend on how the full dataset, expected to be presented at a future medical meeting, compares with rival programmes that have already generated longer-duration weight-loss curves. Investors will want to see durability data beyond four weeks before assigning significant probability to a competitive partnership outcome.